Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
30 April 2026
Investor newsletter

INVESTOR NEWSLETTER – APRIL 2026 (ENGLISH) Open in new window

28 April 2026
General meetings

Notice of the Combined General Meeting on May 19, 2026 Open in new window

28 April 2026
General meetings

Postal voting or proxy form – Combined General Meeting of May 19, 2026 Open in new window

28 April 2026
General meetings

Information regarding the nomination of Françoise de Craecker for the position of director submitted to the Annual Shareholders’ Meeting on May 19, 2026 Open in new window

28 April 2026
General meetings

Supplementary statutory auditors’ report on the issuance, with cancellation of preferential subscription rights, of new ordinary shares each attached to a share subscription warrant (the “ABSA”) and prepaid share subscription warrants each attached to a share subscription warrant (the “Prepaid Units”) (FR) Open in new window

28 April 2026
General meetings

Statutory auditors’ report on the capital increase reserved for members of a company savings plan (FR) Open in new window

28 April 2026
General meetings

Statutory auditors’ report on the authorization to grant existing or newly issued free shares (FR) Open in new window

28 April 2026
General meetings

Statutory auditors’ report on the authorization to grant stock subscription and/or purchase options (FR) Open in new window

28 April 2026
General meetings

Statutory auditors’ report on the issuance of share subscription warrants (BSA), subscription and/or acquisition warrants for new and/or existing shares (BSAANE), and/or redeemable subscription and/or acquisition warrants for new and/or existing shares (BSAAR), with cancellation of preferential subscription rights (FR) Open in new window

28 April 2026
General meetings

Statutory auditors’ report on the issuance of shares and various securities with maintenance and/or cancellation of preferential subscription rights (FR) Open in new window

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 27
  • View next 9 articles
© 2026 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page